科源制药 (301281.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

57.4x

Market Cap

CNY 4.76B

MomentumView details →

1D Return

−0.20%

YTD Return

+59.59%

RSI (14)

57.8

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

57.4x

Market Cap

CNY 4.76B

RSI (14)

57.8

MomentumView details →

1D Return

−0.20%

YTD Return

+59.59%

ProfitabilityView details →

Gross Margin

55.46%

Net Margin

5.25%

EBITDA Margin

18.88%

ROE (TTM)

1.69%

ROA (TTM)

1.31%

Asset Turnover

0.26x

GrowthView details →

Revenue YoY

+4.59%

EPS YoY

−61.63%

FCF YoY

+82.61%

Revenue CAGR 3Y

−3.48%

EPS CAGR 3Y

−48.84%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.11x

Current Ratio

3.05x

Quick Ratio

2.46x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

448.33M

Net Income (TTM)

23.54M

Op. CF (TTM)

75.14M

Latest newsMore news →

Keyuan Pharmaceutical's wholly-owned subsidiary Linuo Pharmaceutical received drug registration certificates from the National Medical Products Administration for Empagliflozin and Metformin Hydrochloride Extended-Release Tablets (III) and (IV), with approval numbers Guoyao Zhunzi H20265843 and H20265844.2d ago

Keyuan Pharmaceutical disclosed that as of June 30, 2026, it had invested 497 million yuan of its IPO proceeds into its fundraising projects, and changed the implementation of the isosorbide mononitrate project to purchase land and build new facilities, increasing total investment to 253 million yuan.10d ago

Similar companies

力星股份300421.SZ 采纳股份301122.SZ 三元生物301206.SZ 横河精密300539.SZ 贝因美002570.SZ 东软载波300183.SZ

Latest newsMore news →

Keyuan Pharmaceutical's wholly-owned subsidiary Linuo Pharmaceutical received drug registration certificates from the National Medical Products Administration for Empagliflozin and Metformin Hydrochloride Extended-Release Tablets (III) and (IV), with approval numbers Guoyao Zhunzi H20265843 and H20265844.2d ago Keyuan Pharmaceutical disclosed that as of June 30, 2026, it had invested 497 million yuan of its IPO proceeds into its fundraising projects, and changed the implementation of the isosorbide mononitrate project to purchase land and build new facilities, increasing total investment to 253 million yuan.10d ago